Fine comparision of the efficacy and safety between GB242 and infliximab in patients with active moderate to severe rheumatoid arthritis: a randomized, double-blind, phase III study
Authors: Li Zhanguo , Liu Yanying , Liu Shengyun , Liu Lin , Gong Xiaowei , Liu Ju , Sun Lingyun , Liu Xiumei , Wu Lijun , Chen Linjie , Wang Ling , Luo Li , Lin Jinying , Tie Ning , Jiang Zhenyu , Wu Jian , Lu Fuai , Sun Hongsheng , Li Xiaomei , Yang Niansheng , Chai Kexia , Wei Hua , Da Zhanyun , Zhao Cheng , Dai Lie , Wang Youlian , Shi Guixiu , Zhang Zhenchun , Song Hui , Liu Yingxue Cathy , Guo Qian 
Published: May 2021

Abstract
Background: This double-blind, active-controlled, randomized, multicenter phase III study evaluated the efficacy, safety and immunogenicity of GB242, an infliximab biosimilar, vs infliximab (Remicade®) reference product in patients with moderate to severe active rheumatoid arthritis (RA) combination with methotrexate (MTX) therapy.Methods: Patients randomised in a 1:1 ratio to receive either GB242 or INF (3 mg/kg intravenous at weeks 0, 2, 6, 14 and 22). MTX was given as an oral weekly dose of 10–25 mg/week with folic acid of 5–10 mg/week, 30 times totally. The primary end point was the American College of Rheumatology 20% (ACR20) response rate at week 30. Therapeutic equivalence of clinical response according to ACR20 criteria was declared if the two-sided 95% CI for the treatment difference was within ±14%. Statistical analysis was also performed with a two-sided 95% CI using ±14% margin. Secondary endpoints included the proportion of patients achieving a week 30 ACR 50 response, ACR70 response, change in Disease Activity Score 28 (DAS28), as well as safety and immunogenicity of GB242.Results: 570 subjects were randomized into GB242 (N=285) or INF (N=285). Finally, 283 subjects in each group were analysed. The primary endpoint was the ACR20 response. In the full analysis population, 177 (62.54%) of 283 patients in the GB242 group (95% CI 56.62% – 68.20%) and 161 (56.89%) of 283 patients in the INF group (95% CI 50.90% – 62.74%) reached ACR20 at week 30. The difference between the two groups was 5.65% with a 95% CI of -2.48 to 13.74, which was within the predefined equivalence margin. The ACR20 response was also similarly shown in the PPS; ACR20 was 71.73% for GB242 and 66.52% for INF, respectively. The difference between the two groups was 5.21% with a 95% CI of -3.33 to 13.6, which was within the predefined equivalence margin. The second endpoints outcomes such as ACR50 response rate, ACR70 response rate and DAS28 were similar between GB242 and INF. ACR50 response for the FAS was 37.12% for GB242 and 32.86% for INF，ACR50 response for the PPS was 42.62% for GB242 and 38.63% for INF. ACR70 response for the FAS was 19.79% for GB242 and 16.96% for INF, ACR70 response for the PPS was 22.78% for GB242 and 20.63% for INF, respectively. The incidence of treatment-emergent adverse events was comparable (77.4% in GB242 vs 80.2% in INF) and detection of antidrug antibodies (ADA) to infliximab up to week 30 (60.8% in GB242 vs 59.4% in INF) was comparable.Conclusions: The efficacy of GB242 appeared to be slightly better than that of INF in terms of ACR20, ACR50, ACR70 at week 30, but the difference was not statistically significant. Moreover, GB242 was well tolerated, with a similar immunogenicity and safety profile comparable to INF. Trial registration: CTR20170127, registered 28 July 2017; NCT04178850, registered 26 Nov 2017-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04178850?term=GB242&draw=2&rank=1